In addition, bladder cancer cells and transplanted tumors with OTUD5 knockdown are more sensitive to the mTOR inhibitor everolimus, which provides new ideas for personalized treatment of bladder cancer patients in the future (Fig. 7). This evidence concerns the gene OTUD5 and urinary bladder carcinoma.